FDA Rejects Avastin as Breast Cancer Drug; Genentech to Conduct New Trial to ID Best Responders | GenomeWeb

Originally published Nov. 18.

By Turna Ray

Genentech has failed to sway the US Food and Drug Administration to keep its oncologic Avastin on the market as a breast cancer treatment, but is planning a clinical trial that will evaluate whether a potential biomarker can determine best responders to the drug.

The FDA this week revoked Avastin's breast cancer indication "after concluding that the drug has not been shown to be safe and effective for that use."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.